World Health Organization : Year 2002 ; Communicable Diseases and Emerging Infectious Diseases ; Department of Control, Prevention, And Eradication, Strategy Development and Monitoring for Eradication and Elimination, No. 2002.34, (P1-P51): Report of the Second Meeting of the Global Alliance to Eliminate Lymphatic Filariasis

By Gro Harlem Brundtland, Dr.

Book Id: WPLBN0000213739
Format Type: PDF eBook:
File Size: 3.32 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 2002 ; Communicable Diseases and Emerging Infectious Diseases ; Department of Control, Prevention, And Eradication, Strategy Development and Monitoring for Eradication and Elimination, No. 2002.34, (P1-P51): Report of the Second Meeting of the Global Alliance to Eliminate Lymphatic Filariasis
Author:	Gro Harlem Brundtland, Dr.
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Harlem Brundtland, Dr, B. G. (n.d.). World Health Organization : Year 2002 ; Communicable Diseases and Emerging Infectious Diseases ; Department of Control, Prevention, And Eradication, Strategy Development and Monitoring for Eradication and Elimination, No. 2002.34, (P1-P51). Retrieved from http://gutenberg.cc/

Description
Medical Reference Publication

Excerpt
The problem More than1 billion people are at risk of lymphatic filariasis (LF). Some 120 million people are infected worldwide, including about 40 million who are incapacitated and disfigured by the disease. LF is endemic in more than 80 countries and territories. Although it does not kill, LF is thought to be the world’s second leading cause of permanent and long-term disability. In recent years, this disease has steadily increased because of the expansion of slum areas and poverty, especially in Africa and the Indian subcontinent. It is primarily a disease of the poor because of its prevalence in remote rural areas and in underprivileged periurban and urban areas and consequently reduces peoples’ ability to work, resulting in loss of family income. The solution Until recently, the diagnosis of LF depended on night blood examinations to detect microfilariae. Now, there is a detection test that can be used at any time of the day, making it more feasible to map the disease than ever before. Treatment is now available in the form of drugs, that are free or low-cost, safe and cost-effective. These drugs kill the microfilariae in the blood and stop the disease in its tracks before the manifestation of debilitating effects. For those who cannot benefit from this prevention strategy, simple methods of hygiene and self-care can dramatically reduce the effects of the disease. With effective tools at our disposal, the time had come for the world to engage in an intensified action against this disease. The World Health Assembly decided in 1997 that LF should be eliminated as a public health problem. WHO proposed a two-pronged strategy for achieving this goal: firstly to interrupt transmission by reducing disease incidence to almost zero and secondly to implement disability management interventions for those who are already suffering from disability. Expanding resources for elimination activities In 1998, the effort to eliminate LF was given a powerful boost when GlaxoSmithKline announced its commitment to collaborate with WHO to support the Global Programme to Eliminate Lymphatic Filariasis, by donating albendazole (one of the drugs used against LF) free of charge for as long as necessary. Subsequently, Merck & Co., Inc., pledged to expand its ongoing Mectizan® Donation Program for onchocerciasis (river blindness) to cover treatment of LF with ivermectin in all African countries where the two diseases occur together.

Table of Contents
CONTENTS Foreword . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Agenda Outline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Participating Organizations and Ministries of Health . . . . . . . . . . . . . . . . . . . . . 7 Abbreviations and Acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Opening Addresss by the Director-General of the World Health Organization . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Inaugural Address by the Minister of Health and Family Welfare, India . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Accountability and Progress. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Dynamic achievements of a successful Global Programme Scaling up elimination activites in the regions New science and research Getting it right at country level: the case of India and the Burkina Faso experience Continuing Support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Key note address on the elimination of lymphatic filariasis in India Effective public-private partnerships: GlaxoSmithKline Mectizan® Donation Program Political Will for the Future. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60 Ministers commit themselves and their governments to the elimination of lymphatic filariasis sustainable development and the elimination of lymphatic filariasis The Bill and Melinda Gates Foundation DFID The elimination of lymphatic filariasis as a strategy for Poverty Alleviation and sustainable development in the Philippines Group Discussions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68 National ownership of the elimination of lymphatic filariasis Elimination of lymphatic filariasis, poverty alleviation and sustainable development - policies and strategies for resource mobilization The global partnership National level partnerships Final Statement . . . . . . . . . . . . . . . . . . . . . . 80 Final statement of the second meeting of the Global Alliance to Eliminate Lymphatic Filariasis